Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 1, 2004, Pages 34-38

  Kagawa, Yoshiyuki ^a   Mukohara, Rika ^a   Hori, Hiroki ^a   Kawasaki, Hajime ^a   Komada, Yoshihiro ^a   Kojima, Michio ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Delayed elimination; Fever; High dose MTX therapy; Methotrexate; Risk factor

Indexed keywords

ANTIPYRETIC AGENT; CREATININE; DICLOFENAC; DIPYRONE; MEFENAMIC ACID; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; FEVER; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HUMANS; INFANT; KIDNEY; MALE; METHOTREXATE; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 3042842739     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0781-6     Document Type: Article

References (10)

1. Bleyer WA (1983) A comprehensive guide to the therapeutic use of methotrexate in bladder cancer. In: Bleyer WA (ed) Pharmanual. PharmaLibri, New Jersey, p.51
2. Bleyer WA (1989) New vistas for leucovorin in cancer therapy. Cancer 63:995
3. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER (2002) Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc Natl Acad Sci U S A 99:13837
4. Herrick AL, Grennan DM, Aarons L (1999) Lack of interaction between methotrexate and penicillins. Rheumatology 38:284
5. Seidel H, Andersen A, Kvaloy JT, Nygaard R, Moe PJ, Jacobsen G, Lindqvist B, Slordal L (2000) Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res 24:193
6. Thyss A, Milano G, Kubar J, Namer M (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 8475:256
7. Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42:1322
8. Troche G, Sacquin P, Achkar A, Korach JM, Laaban JP, Gajdos P (1991) Severe methotrexate poisoning (in French). Presse Med 20:1724
9. Uwai Y, Saito H, Inui K (2000) Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 409:31
10. Waltham MC, Holland JW, Robinson SC, Winzor DJ, Nixon PF (1988) Direct experimental evidence for competitive inhibition of dihydrofolate reductase by methotrexate. Biochem Pharmacol 37:535